Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Priority and Status of Claims
1. This application is a 371 of PCT/US2022/020038 03/11/2022, which claims benefit of 63/185,464 05/07/2021 and 63/160,412 03/12/2021.
2. Claim 1 is pending in the application.
Claim Rejections - 35 USC § 112
3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Claim 1 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112, first paragraph (pre-
AIA ), because the specification does not reasonably provide enablement of the instant
“glycine transporter 1 inhibitor” without limitation (i.e., no named compounds or formula).
The specification does not enable any person skilled in the art to which it pertains, or with
which it is most nearly connected, to make the invention commensurate in scope with
these claims.
ln In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining
whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first
paragraph, have been described. They are:
1. the nature of the invention,
2. the state of the prior art,
3. the predictability or Iack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of the skill in the art.
In the instant case:
The nature of the invention
The nature of the invention is a method of use using “glycine transporter 1 inhibitor” without limitation (i.e., no named compounds or formula), see claim 1.
The state of the prior art and the predictability or Iack thereof in the art
The state of the prior art is Quisel et al. US 2024/0269132, it discloses a compound of
formula (I) as a glycine transporter 1 inhibitor, see column 3.
The amount of direction or guidance present and the presence or absence
of working examples
The only direction or guidance present in the instant specification is the description of a number of “glycine transporter 1 inhibitor” on pages 6-12 of the specification. There is no data present in the instant specification for the “glycine transporter 1 inhibitor” without limitation (i.e., no named compound or formula).
The breadth of the claims
The instant breadth of the rejected claims is broader than the disclosure,
specifically, the instant “glycine transporter 1 inhibitor” are without limitation (i.e., no named compound or formula).
The quantity or experimentation needed and the Ievel of skill in the art
While the level of the skill in the chemical arts is high, it would require
undue experimentation of one of ordinary skill in the art to resolve any “glycine transporter 1 inhibitor” without limitation. There is no guidance or working examples present for constitutional any “glycine transporter 1 inhibitor” without limitation for the instant invention. Incorporation of the limitation of “glycine transporter 1 inhibitor” supported by specification into claim 1 would overcome this rejection.
4. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Claim Rejections - 35 USC § 103
5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating
obviousness or non-obviousness.
This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).
Claim 1 is rejected under 35 U.S.C. 103(a) as being obvious over Quisel et al.
US 2024/0269132 A1. It is noted that Quisel et al. ‘132 is a 102 (a)(2) reference.
Applicants claim a method of treating polycythemia in a subject, the method comprising administering to the subject a pharmaceutical composition comprising one or more glycine transporter 1 (GlyT1) inhibitor, or a pharmaceutically acceptable salt thereof, or a prodrug of the one or more GlyT1 inhibitor or its salt, see claim 1.
Determination of the scope and content of the prior art (MPEP §2141.01)
Quisel et al. ‘132 discloses methods of use for treating polycythemia using a
Number of compound of formula (I)-(IV), which are glycine transporter 1 (GlyT1)
inhibitor, see columns 3-5. A specific compound has been exemplified, see column 92.
Determination of the difference between the prior art and the claims (MPEP §2141.02)
The difference between instant claims and Quisel et al. ‘132 is that the instant claims are embraced within the scope of Quisel et al. ‘132. It is noted that the instant claim is silent the scope of glycine transporter 1 (GlyT1) inhibitor.
Finding of prima facie obviousness-rational and motivation (MPEP §2142-2143)
One having ordinary skill in the art would find the claim 1 prima facie obvious because one would be motivated to employ the methods of use of Quisel et al. ‘132 to obtain instant invention.
The motivation to make the claimed methods of use derived from the known methods of use of Quisel et al. ‘132 would possess similar activity to that which is claimed in the reference.
Double Patenting
6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).
Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
Claim 1 is provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of Quisel et al. co-pending application No. 18/923,904. Although the conflicting claims are not identical, they are not patentably distinct from each other and reasons are as follows.
Applicants claim a method of treating polycythemia in a subject, the method comprising administering to the subject a pharmaceutical composition comprising one or more glycine transporter 1 (GlyT1) inhibitor, or a pharmaceutically acceptable salt thereof, or a prodrug of the one or more GlyT1 inhibitor or its salt, see claim 1.
Quisel et al. ‘904 claims a method of treating polycythemia in a subject, the
method comprising administering to the subject a pharmaceutical composition
comprising a compound having formula:
PNG
media_image1.png
306
342
media_image1.png
Greyscale
(i.e., a glycine transporter 1 (GlyT1) inhibitor), or a
pharmaceutically acceptable salt thereof, see claim 1.
The difference between instant claims and Quisel et al. ‘904 is that the instant claims are embraced within the scope of Quisel et al. ‘904. It is noted that the instant claim is silent the scope of glycine transporter 1 (GlyT1) inhibitor.
One having ordinary skill in the art would find the claim 1 prima facie obvious because one would be motivated to employ the methods of use of Quisel et al. ‘904 to obtain instant invention.
The motivation to make the claimed methods of use derived from the known methods of use of Quisel et al. ‘904 would possess similar activity to that which is claimed in the reference.
This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/REI TSANG SHIAO/
Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1629
December 30, 2025